![Pedro Granadillo](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Pedro Granadillo
Fondateur chez
Umbria Pharmaceuticals, LLC
Fortune : 203 610 $ au 31/08/2026
Profil
Pedro P.
Granadillo was the founder of Neumentum, Inc. (2017) with the title of Director.
Mr. Granadillo is also the founder of Umbria Pharmaceuticals, LLC.
Former positions include Chairman at Kirax Corp.
(2009-2010), Chairman at Aura Biosciences, Inc., Director at First Indiana Corp.
(2002-2008), Director at Noven Pharmaceuticals, Inc. (2004-2009), Independent Director at NPS Pharmaceuticals, Inc. (2011-2015), Independent Director at Haemonetics Corp.
(2004-2019), Independent Director at Dendreon Corp.
(2011-2014), Director at First Indiana Bank, NA (2002-2007), Independent Director at Capricor Therapeutics, Inc. (2013), Director at Health Sciences Acquisitions Corp., Independent Director at Health Sciences Acquisitions Corp.
2, Independent Director at Rocket Pharmaceuticals, Inc. (2018-2025), and SVP-Global Manufacturing & Human Resources at Eli Lilly & Co. (1970-2004).
Education includes an undergraduate degree from Purdue University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 18/06/2025 | 54 734 ( 0,05% ) | 203 610 $ | 31/08/2026 |
Postes actifs de Pedro Granadillo
| Sociétés | Poste | Début |
|---|---|---|
Umbria Pharmaceuticals, LLC | Fondateur | - |
Anciens postes connus de Pedro Granadillo
| Sociétés | Poste | Fin |
|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 30/09/2025 |
| HAEMONETICS CORPORATION | Directeur/Membre du Conseil | 25/07/2019 |
| NPS PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/01/2015 |
| DENDREON CORPORATION | Directeur/Membre du Conseil | 04/03/2014 |
| CAPRICOR THERAPEUTICS, INC. | Directeur/Membre du Conseil | 20/11/2013 |
Formation de Pedro Granadillo
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
71
Relations au 1er degré
16
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 16 |
|---|---|
First Indiana Corp.
 First Indiana Corp. Major BanksFinance Operates as bank holding company whose subsidiary provides banking services | Finance |
Eli Lilly & Co.
 Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
Noven Pharmaceuticals, Inc.
 Noven Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research, development, manufacture, marketing and sale of transdermal pharmaceutical products | Commercial Services |
NPS Pharmaceuticals, Inc.
 NPS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products for the treatments of rare diseases | Health Technology |
Haemonetics Corp.
 Haemonetics Corp. Medical SpecialtiesHealth Technology Designs, manufactures, markets and services blood processing systems | Health Technology |
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Discovers, develops and commercializes novel products for the treatment of cancer | Health Technology |
Kirax Corp.
 Kirax Corp. Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes pharmaceutical products | Health Technology |
Aura Biosciences, Inc.
 Aura Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company leveraging novel targeted oncology platform to develop new standard of care across multiple cancer indications | Health Technology |
First Indiana Bank, NA
 First Indiana Bank, NA Major BanksFinance Operates as a nationally chartered commercial bank | Finance |
Purdue University
 Purdue University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Capricor Therapeutics, Inc.
 Capricor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops innovative products for the treatment of cardiovascular diseases | Health Technology |
Umbria Pharmaceuticals, LLC | |
Neumentum, Inc.
 Neumentum, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Rocket Pharmaceuticals, Inc.
 Rocket Pharmaceuticals, Inc. BiotechnologyHealth Technology Provides gene therapy services | Health Technology |
Health Sciences Acquisitions Corp.
 Health Sciences Acquisitions Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
Health Sciences Acquisitions Corp. 2
 Health Sciences Acquisitions Corp. 2 Financial ConglomeratesFinance Operates as a blank check company | Finance |
